信达生物（01801）公布，新一代ROS1酪氨酸激酶抑制剂（TKI）达伯乐® （己二酸他雷替尼胶囊）的第二项新药上市申请（NDA）获中国国家药品监督管理 ...

An isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene and tested for its ...

Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

The appraisal committee has prepared final draft guidance (FDG) on crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) and submitted it to NICE. The FDG has ...

In December 2024, Dovbleron was approved by the NMPA for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC ... to see that Dovbleron ...

It is the only ROS1 TKI with FDA breakthrough therapy designation for locally advanced or metastatic ROS1-positive NSCLC. The FDA has granted priority review to an NDA for taletrectinib in the ...

(NYSE: NUVB) submitted an NDA for taletrectinib to the U.S. FDA for the treatment of patients with advanced ROS1-positive NSCLC (line agnostic, full approval ... References [i] Zhang et al. Prevalence ...